Clinical practice guidelines for the treatment of unresectable non- small-cell lung cancer

Journal of Clinical Oncology

Volumn 15, Issue 8, 1997, Pages 2996-3018

  Somerfield, Mark R ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MEDICAL EXPERT; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURGICAL TECHNIQUE; SURVIVAL RATE;

EID: 0030836373     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.8.2996     Document Type: Article

References (159)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics. Ca Cancer J Clin 65:5-27, 1996
2. Ries LAG, Hankey BF, Miller BA, et al: National Cancer Institute, Cancer Statistics Review. Bethesda, MD, National Institutes of Health, 1991, pp 1973-1988
3. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327:1434-1441, 1992
4. Ihde DC, Minna JD: Non-small cell lung cancer, I Biology, diagnosis, and staging. Curr Probl Cancer 15:61-104, 1991
5. Martini N, Flehinger BJ: The role of surgery in N2 lung cancer. Surg Clin North Am 67:1037-1049, 1987
6. Perez CA, Stanley K, Grundy G, et al: Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Report by the Radiation Therapy Oncology Group. Cancer 50:1091-1099, 1992
7. Mountain CF: Prognostic implications of the international staging system for lung cancer. Semin Oncol 3:236-245, 1988
8. Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500, 1990
9. Relman AS: Assessment and accountability: The third revolution in medical care. N Engl J Med 319:1220-1222, 1988
10. Raby B, Pater J, Mackillop WJ: Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 13:1904-1911, 1995
11. Mackillop WJ, Dixon P, Zhou Y, et al: Variations in the management and outcome of non-small cell lung cancer in Ontario. Radiother Oncol 32:106-115, 1994
12. Greenberg ER, Chute CG, Baron JA, et al: Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural areas. N Engl J Med 318:612-617, 1988
13. McNeil BJ, Weichselbaum R, Pauker SG: Fallacy of five-year survival in lung cancer. N Engl J Med 299:1397-1401, 1978
14. Pfister DG, Wells CK, Chan CK, et al: Classifying clinical severity to help solve problems of stage migration in nonconcurrent comparisons of lung cancer therapy. Cancer Res 50:4664-4669, 1990
15. Ihde DC, Minna JD: Non-small cell lung cancer part II: Treatment. Curr Probl Cancer 15:109-154, 1991
16. Canadian Medical Association: The Canadian task force on the periodic health examination. Can Med Assoc J 121:1193-1254, 1979
17. American Society of Clinical Oncology Ad Hoc Colony Stimulating Factor Guideline Expert Panel: American Society of Clinical Oncology recommendations for the use of hematopoietic colony stimulating factors, evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
18. Sackett DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95:2S-4S, 1989 (suppl 2)
19. Cook DL, Guyatt GH, Laupacis A, et al: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102:S305-S311, 1992 (suppl 4)
20. Kreyberg L: The World Health Organization histological typing of lung tumors. Am J Clin Pathol 77:123-136, 1982
21. American Joint Committee on Cancer: Lung (ed 3). Philadelphia, PA, Lippincott, 1988
22. Deslauriers J: Survival in patients undergoing tracheal sleeve pneumonectomy for bronchogenic carcinoma. J Thorac Cardiovasc Surg 84:489-496, 1982
23. Inoue H, Shohtsu A, Koide S, et al: Resection of the superior vena cava for primary lung cancer: 5 years' survival. Ann Thorac Surg 50:661-662, 1990
24. DeMeester TR, Albertucci M, Dawson PJ, et al: Management of tumor adherent to the vertebral body. J Thorac Cardiovasc Surg 97:373-378, 1989
25. Rosell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153-158, 1994
26. Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86:673-680, 1994
27. American Joint Committee on Cancer: General Information on Cancer Staging and End Results Reporting (ed 3). Philadelphia, PA, Lippincott, 1988
28. Karnofsky DA, Abelmann WH, Craver LF et al: The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1:634-656, 1948
29. Outcomes Working Group HSRC, American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679, 1996
30. Hollen PJ, Gralla RJ, Kris MG, et al: Quality of life during clinical trials: Conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 2:213-222, 1994
31. Aaronson NK, Ahmedzai S, Begman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
32. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
33. Jaakkimainen L, Goodwin PJ, Pater J, et al: Counting the costs of chemotherapy in a national cancer institute of Canada randomized trial in non-small-cell lung cancer. J Clin Oncol 8:1301-1309, 1990
34. Pugatch RD: Radiological evaluation in chest malignancies. A review of imaging modalities. Chest 107:S294-S297, 1995 (suppl 6)
35. Quint LE, Francis IR, Wahl RL, et al: Preoperative staging of non-small cell carcinoma of the lung: Imaging methods. AJR 164:1349-1359, 1995
36. Dales RE, Stark RM, Sankaranarayanan R: Computed tomography to stage lung cancer. Am Rev Respir Dis 141:1096-1101, 1990
37. Dillemans B, Deneffe G, Verschakelen J, et al: Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. Eur J Cardiothorac Surg 8:37-42, 1994
38. Ginsberg RJ: Invasive and noninvasive techniques of staging potentially operable lung cancer. Semin Surg Oncol 6:244-247, 1990
39. Ikezoe J, Kadowaki K, Morimoto S, et al: Mediastinal lymph node metastases from non-small cell bronchogenic carcinoma: Reevaluation with CT. J Comput Assist Tomogr 14:340-344, 1990
40. Patterson GA, Ginsberg RJ, Poon PY, et al: A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J Thorac Cardiovasc Surg 94:679-684, 1987
41. The Canadian Lung Oncology Group: Investigation for mediastinal disease in patients with apparently operable lung cancer. Ann Thorac Surg 60:1382-1389, 1995
42. Michel F, Soler M, Imhof E, et al: Initial staging of non-small cell lung cancer: Value of routine radioisotope bone scanning. Thorax 46:469-473, 1991
43. Quinn DL, Ostrow LB, Porter DK, et al: Staging of non-small cell bronchogenic carcinoma: Relationship of the clinical evaluation to organ scans. Chest 89:270-275, 1986
44. Matthews MJ, Kanhouwa S, Pickren J, et al: Frequency of residual and metastatic tumors in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 4:63-67, 1973
45. Mintz BJ, Tuhrim TS, Alexander S, et al: Intracranial metastases in the initial staging of bronchogenic carcinoma. Chest 86:850-853, 1984
46. Butler AR, Leo JS, Lin JP, et al: The value of routine cranial computed tomography in neurologically intact patients with primary carcinoma of the lung. Radiology 131:399-401, 1979
47. Colice GL, Birkmeyer JD, Black WC, et al: Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest 108:1264-1271, 1995
48. Silvestri G, Littenberg B, Colice GL: The clinical evaluation for detecting metastatic lung cancer: A meta-analysis. Am J Respir Crit Care Med 152:225-230, 1995
49. Nielsen ME, Heaston DK, Dunnick NR, et al: Preoperative CT evaluation of adreanal glands in non-small cell bronchogenic carcinoma. AJR 139:317-320, 1982
50. Oliver TW, Bernardino ME, Miller JI, et al: Isolated adrenal masses in non-small cell bronchogenic carcinoma. Radiology 153:217-218, 1984
51. Ettinghausen SE, Burt ME: Prospective evaluation of unilateral adrenal masses in patients with operable non-small cell lung cancer. J Clin Oncol 9:1462-1466, 1991
52. Gillams A, Roberts CM, Shaw P, et al: The value of CT scanning and percutaneous fine needle aspiration of adrenal masses in biopsy-proven lung cancer. Clin Radiol 46:18-22, 1992
53. Silverman SG, Mueller PR, Pinkney LP: Predictive value of image-guided adrenal biopsy: Analysis of results of 101 biopsies. Radiology 187:715-718, 1993
54. Francis IR, Smid A, Gross MD, et al: Adrenal masses in oncologic patients: functional and morphologic evaluation. Radiology 166:353-356, 1988
55. Burt M, Heelan RT, Coit D, et al: Prospective evaluation of unilateral adrenal masses in patients with operable non-small cell lung cancer. J Thorac Cardiovasc Surg 107:584-589, 1994
56. Sparup J, Friis M, Brenoe J, et al: Computed tomography and the TNM classification of lung cancer. Scand J Thorac Cardiovasc Surg 24:207-211, 1990
57. McNeil BJ, Pauker SG, Sox HC, et al: On the elicitation of preferences for alternative therapies. N Engl J Med 306:1259-1262, 1982
58. Yellen SB, Cella DF: Someone to live for social well-being parenthood status and decision-making in oncology. J Clin Oncol 13:1255-1264, 1995
59. Grilli R, Oxman AD, Jullian JA: Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993
60. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
61. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323:940-945, 1990
62. Dillman RO, Seagren SL, Herndon J, et al: Improved survival in stage III non-small cell lung cancer: Seven year follow-up of CALGB 8433. J Natl Cancer Inst 88:1210-1215, 1996
63. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial of regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
64. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 14:1065-1070, 1996
65. Schaake-Koning C, van den Bogaert W, Dalesio W, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
66. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993
67. Bonomi P, Kim K, Chang A, et al: Phase III trial comparing etoposide (E), cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus Taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Group (ECOG) trial. Proc Am Soc Clin Oncol 15:382, 1996 (abstr)
68. Le Chevalier T, Brisgard D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multi-center trial including 612 patients. J Clin Oncol 12:360-367, 1994
69. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized phase II trial of cisplatin (CDDP) versus CDDP plus Navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): Report of the Southwest Oncology Group study (SWOG-9308). Proc Am Soc Clin Oncol 15:374, 1996 (abstr)
70. Ellis PA, Smith IE, Hardy JR, et al: Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 71:366-370, 1995
71. Hollen PJ, Gralla RJ, Kris MG, et al: Quality of life in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A:S51-S58, 1993 (suppl 1)
72. Hollen PJ, Gralla RJ, Kris MG, et al: Measurement of quality of life in patients with lung cancer in multi center trials of new therapies: Psychometric assessment of the Lung Cancer Symptom Scale (LCSS). Cancer 73:2087-2098, 1994
73. Kris MG, Gralla RJ, Potanovich LM, et al: Assessment of pretreatment symptoms and improvement after EDAM + mitomycin+vinblastine in patients with inoperable non-small lung cancer. Proc Am Soc Clin Oncol 9:229, 1990 (abstr)
74. Tummarello D, Graziano F, Isidori P, et al: Symptomatic, stage IV, non-small cell lung cancer (NSCLC): Response, toxicity, performance status change and symptom relief in patients treater with cisplatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol 35:249-253, 1995
75. Finkelstein DM, Ettinger DS, Ruckdeschel JC: Long-term survivors in metastatic non-small lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 4:702-709, 1986
76. O'Connell JP, Kris MG, Gralla RJ, et al: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 4:1604-1614, 1986
77. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-stage non-small cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
78. Paesmans M, Sculier JP, Libert P, et al: Prognostic factors for survival in advanced non-small cell lung cancer: Univariate and multivariate analysis including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 13:1221-1230, 1995
79. DeWys WD, Begg C, Lavin PT, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69:491-497, 1980
80. Marino P, Preatoni A, Cantoni A, et al: Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: A quality and meta-analysis study. Lung Cancer 13:1-12, 1995
81. Klastersky J, Sculier JP, Ravez P, et al: A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung carcinoma. J Clin Oncol 4:1780-1786, 1986
82. Klastersky J, Sculier JP, Lacroix H, et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer -protocol 07861. J Clin Oncol 8:1556-1562, 1990
83. Shinkai T, Saijo N, Eguchi K, et al: Cisplatin and vindesine combination chemotherapy for non-small lung cancer: A randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res 77:782-789, 1986
84. Davis S, Rambotti P, Park YK: Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung. Cancer Treat Rep 65:955-958, 1981
85. Gandara DR, Crowley J, Livingston RB, et al: Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: A phase II study of the Southwest Oncology Group. J Clin Oncol 11:873-878, 1993
86. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10:16-20, 1992
87. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
88. Anderson H, Lund B, Bach F, et al: Single-Agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994
89. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12:1238-1244, 1994
90. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage II and IV non-small lung cancer. J Clin Oncol 12:1232-1237, 1994
91. Cerny T, Kaplan S, Pavlidis N, et al: Docetaxel (taxotere) is active in non-small cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 70:384-387, 1994
92. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75:968-972, 1995
93. Masuda N, Fukuoka M, Takada M, et al: CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol 10:1775-1780, 1992
94. Masuda N, Fukuoka M, Kudoh S, et al: Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 12:90-96, 1994
95. Le Chevalier T, Belli L, Monnier A, et al: Phase II study of docetaxel (Taxotere) and cisplatin in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:350, 1995 (abstr)
96. Zalcberg JR, Bishop JF, Milward MJ, et al: Preliminary results of the first phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:351, 1995 (abstr)
97. Cole JT, Gralla RJ, Marques C, et al: Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:357, 1995 (abstr)
98. Shepard F, Burkes R, Cormier Y, et al: Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer. Semin Oncol 23:48-54, 1996 (suppl 10)
99. Steward WP, Dunlop DJ, Dabouis G, et al: Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: Preliminary results. Semin Oncol 23:43-47, 1996 (suppl 10)
100. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer (NSCLC): A phase II toxicity, response, and survival analysis (FCCC 93-024). J Clin Oncol 13:1860-1870, 1995
101. Johnson DH, Paul DM, Hande KR, et al: Paclitaxel plus carboplatin in advanced non-small cell lung cancer - Phase II trial. J Clin Oncol 14:2054-2060, 1996
102. Giaccone G, Splinter T, Postumus P, et al: Paclitaxel-cis-platin versus teniposide-cisplatin in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15:373, 1996 (abstr)
103. Colvin M: Alkylating Agents and Platinum Antitumor Compounds (ed 3). Philadelphia, PA, Lea & Febiger, 1993
104. Calabresi P, Chabner BA: Chemotherapy of Neoplastic Disease (ed 9). New York, NY, McGraw-Hill, 1996
105. Klastersky J, Sculier JP, Bureau G, et al: Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 7:1087-1092, 1989
106. Anderson TM, Moy PM, Holmes EC: Factors affecting survival in superior sulcus tumors. J Clin Oncol 4:1598-1603, 1986
107. Buccheri GF, Ferrigno D, Curcio A, et al: Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Cancer 63:428-432, 1989
108. Lad TE, Nelson R, Diekamp U, et al: Immediate versus postponed combination chemotherapy (CAMP) for unresectable non-small cell lung cancer: A randomized trial. Cancer Treat Rep 65:973-978, 1981
109. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 13:645-651, 1995
110. Gridelli C, Airoma G, Incoronato P, et al: Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small cell lung cancer. Cancer Chemother Pharmacol 30:212-214, 1992
111. Dansin E, Sokpoh H, Georges H, et al: Mitomycin, ifosfamide, cisplatin (MIC) as second-line regimen in advanced non-small cell lung cancer (NSCLC). Ann Oncol 3:35, 1992 (abstr)
112. Pronzato P, Landucci M, Vaira F, et al: Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer. Anticancer Res 14:1413-1415, 1994
113. Ruckdeschel J, Wagner H, Williams C, Jr., et al: Second-line chemotherapy for resistant, metastatic, non-small cell lung cancer (NSCLC): The role of Taxol. Proc Am Soc Clin Oncol 13:357, 1994 (abstr)
114. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989
115. Rossing TH, Rossing RG: Survival in lung cancer. An analysis of the effects of age, sex, resectability, and histopathological type. Am Rev Respir Dis 126:771-777, 1982
116. Rosenthal SA, Curran WJ: The significance of histology in non-small cell lung cancer. Cancer Treat Rev 17:409-425, 1990
117. Ruckdeschel JC, Linnoila RI, Mulshine JL, et al: The impact of neuroendocrine (Ne) and epithelial (Epi) differentiation on response and survival in lung cancer: The ECOG experience. Proc Am Soc Clin Oncol 10:248, 1991 (abstr)
118. Shaw GL, Gazdar AF, Phelps R, et al: Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res 53:5181-5187, 1993
119. Wolf J, Spear P, Yesner R, et al: Nitrogen mustard in the palliative treatment of inoperable bronchogenic carcinoma. Am J Med 29:1008-1022, 1960
120. Kubota K, Furuse K, Kawahara M, et al: Role of radiotherapy in combined modality treatment of locally advanced non-small cell lung cancer. J Clin Oncol 12:1547-1552, 1994
121. Johnson DH, Einhorn LH, Bartolucci A, et al: Thoracic radiotherapy does not prolong survival in patients with locally advanced unresectable non-small cell lung cancer. Ann Intern Med 11:33-38, 1990
122. Perez CA, Bauer M, Edelstein S, et al: Impact of local tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 12:538-547, 1986
123. Sause WT, Scott C, Byhardt RW, et al: Recursive partitioning analysis of 1,592 patients on four RTOG studies in non-small cell lung cancer. Proc Am Soc Clin Oncol 12:336, 1993 (abstr)
124. Byhardt RW, Scott DB, Ettinger DS, et al: Concurrent hyperfractionated irradiation and chemotherapy for unresectable non-small cell lung cancer. Results of Radiation Therapy Oncology Group (RTOG) 90-15. Cancer 75:2337-2344, 1995
125. Byhardt RW, Martin L, Pajak TF, et al: The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer. Results of the Radiation Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys 27:537-544, 1993
126. Fowler JF: Fractionation in radiation therapy. Semin Radiat Oncol 2:16, 67, 1992
127. Thames HD, Withers HR, Peters LJ, et al: Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationship. Int J Radiat Oncol Biol Phys 8:219-226, 1982
128. Diener-West M, Pajak TF, Bauer M, et al: Randomized dose-searching phase I, II trials of fractionation in radiation therapy for cancer. J Natl Cancer Inst 83:1065-1071, 1991
129. Perez CA, Stanley K, Rubin P, et al: A prospective randomized study of various irradiation dose fractionation schedules in the treatment of inoperable non-small cell lung cancer. Cancer 24:2744-2753, 1980
130. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non small cell lung cancer; First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
131. Cox JD, Azarnia N, Byhardt RW, et al: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 to 79.2 Gy. Possible survival benefit with >69.6Gy in favorable patients with RTOG stage III non-small cell lung carcinoma. Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543-1555, 1990
132. Saunders MI, Dische S: Continuous hyperfractionated accelerated radiotherapy (CHART) in non-small cell lung carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 19:1211-1215, 1990
133. Sause WT, Scott C, Taylor S, et al: RTOG 8808 ECOG 4588, preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer with a minimum of 3 years follow-up. J Natl Cancer Inst 87:198-205, 1995
134. Anonymous: Inoperable non-small cell lung cancer (NSCLC): A Medical Research Council randomized trial of palliative radiotherapy with two fractions vs. ten fractions. Br J Cancer 63:265-270, 1991
135. Simpson JR, Francis ME, Perez-Tamayo R, et al: Palliative radiotherapy for inoperable carcinoma of the lung: Final report from the RTOG multi-institutional trial. Int J Radiat Oncol Biol Phys 11:751-758, 1985
136. Smalley SR, Schray MF, Laws ER, et al: Adjuvant radiation therapy after surgical resection of solitary brain metastasis: Association with pattern of failure and survival. Int J Radiat Oncol Biol Phys 13:1611-1616, 1987
137. Harpole D, Amos A, Alexander E, et al: Harvard Medical School stage of the primary is important when treating isolated brain metastasis from lung cancer. Proc Am Soc Clin Oncol 15:382, 1996 (abstr)
138. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int. J Rad Oncol Biol Phys 29:711-717, 1994
139. Twomey P, Montgomery C, Clark O: Successful treatment of adreanal metastasis from large-cell carcinoma of the lung. JAMA 248:581-583, 1982
140. Raviv G, Klien E, Yellin A, et al: Surgical treatment of solitary adrenal metastases from lung carcinoma. J Surg Oncol 43:123-124, 1990
141. Reyes L, Parvez Z, Nemoto T, et al: Adrenalectomy for adrenal metastasis from lung carcinoma. J Surg Oncol 44:32-34, 1990
142. Walsh GL, O'Connor M, Willis KM, et al: Is follow-up of lung cancer patients medically indicated and cost-effective. Ann Thorac Surg 60:1563-72, 1995
143. Virgo KS, McKirgan LW, Caputo M, et al: Post treatment management options for patients with lung cancer. Ann Surg 222:700-710, 1995
144. Del Turco MA, Palli D, Cariddi A, et al: Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial. National Research Council Project on Breast Cancer. JAMA 271:1593-1957, 1994
145. GIVIO Investigators: Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 271:1587-1592, 1994
146. Thomas P, Rubinstein L: Cancer recurrence after resection T1N0 non-small cell lung cancer. Ann Thorac Surg 49:242-247, 1990
147. Wynder DI, Graham EA: Tobacco smoking as a possible etiologic factor in bronchogenic cancer. JAMA 143:329-36, 1950
148. Doll R, Hill AB: Smoking and carcinoma of the lung (preliminary report). Br Med J 117:39-48, 1950
149. American Cancer Society: American Cancer Society Cancer Facts and Figures - 1996. Atlanta, GA, American Cancer Society, 1996
150. Silverman S, Greenspan D, Gorsky M: Tobacco usage in patients with head and neck carcinomas: A follow-up study on habit changes and second primary oral/oropharyngeal cancers. J Am Dent Assoc 106:33-35, 1983
151. Schottenfeld D, Grant RC, Wynder EL: The role of alcohol and tobacco in multiple primary cancers of the upper digestive system, larynx and lung: A prospective study. Prev Med 3:277-293, 1974
152. Fiore MC, Jorenby DE, Baker TB, et al: Tobacco dependence and the nicotine patch: Clinical guidelines for effective use. JAMA 268:2687-2694, 1992
153. Hennekens CH, Buring JE, Manson JE, et al: Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334:1145-1149, 1996
154. Omenn GS, Goodman GE, Thornquist MD, et al: Effects of combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996
155. Pastorino U, Infante M, Maioli M, et al: Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11:1216-1222, 1993
156. Lippman SM, Kessler JF, Meyskens FL: Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 71:493-515, 1987
157. Morton RF, Jett JR, McGinnis WL, et al: Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 115:681-686, 1991
158. Wolf M, Hans K, Becker H, et al: Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer. Semin Oncol 21:42-47, 1994 (suppl 4)
159. Mattson K, Holsti LR, Holsti P, et al: Inoperable non-small cell lung cancer: Radiation with or without chemotherapy. Eur J Cancer Clin Oncol 24:477-482, 1988